Intraocular pressure lowering effect of brinzolamide 1.0% as adjunctive therapy to latanoprost 0.005% in patients with open angle glaucoma or ocular hypertension: an uncontrolled, open-label study

2005 ◽  
Vol 21 (4) ◽  
pp. 503-507 ◽  
Author(s):  
Nobuyuki Shoji ◽  
Hiroko Ogata ◽  
Hideo Suyama ◽  
Hitoshi Ishikawa ◽  
Hiromasa Suzuki ◽  
...  
Keyword(s):  
Intraocular Pressure ◽  
Ocular Hypertension ◽  
Adjunctive Therapy ◽  
Open Angle Glaucoma ◽  
Open Angle ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Lowering Effect ◽  
Pressure Lowering

scholarly journals Adjunctive therapy with brinzolamide in patients on travoprost treatment

2011 ◽  
Vol 64 (5-6) ◽  
pp. 310-314
Author(s):  
Nikola Babic ◽  
Veljko Andreic ◽  
Aleksandar Miljkovic ◽  
Vladimir Canadanovic ◽  
Sava Barisic
Keyword(s):  
Intraocular Pressure ◽  
Ocular Hypertension ◽  
Adjunctive Therapy ◽  
Open Angle Glaucoma ◽  
Combined Therapy ◽  
Previous Treatment ◽  
Open Angle ◽  
Open Label ◽  
Blurred Vision ◽  
Safety And Efficacy

Introduction. This study was aimed at evaluating the safety and efficacy of brinzolamide 1% suspension (Azopt? 1%) and travoprost 0.004% (Travatan?) combined therapy in patients with open-angle glaucoma or ocular hypertension who are in need of additional intraocular pressure lowering. Material and methods. This is a prospective, three-month, open-label, clinical study. Forty patients (80 eyes) with primary open-angle glaucoma or ocular hypertension on Travatan? treatment and with unsatis-factory results in lowering intraocular pressure were included in the study. The qualifying intraocular pressure on previous treatment with Travatan? (at least 6 weeks) was 22-36 mmHg in at least one eye at 8 a.m. intraocular pressure measurements at three eligibility visits. The patients received brinzolamide 1% twice a day in addition to travoprost 0.004% given once a day in the evening for 3 months. The follow-up examinations assessing the safety and efficacy of combined therapy of brinzolamide 1% and travoprost 0.004% were performed after 1 and 3 months. Results. Adjunctive therapy with brinzolamide resulted in statistically significant reductions in intraocular pressure from the travoprost baseline at all visits. Treatment with brinzolamide/travoprost caused statistically significant sustained reduction in intraocular pressure with the reduction of 17.39% (p<0.001) after 4 weeks and 20.08% (p<0.001) after 12 weeks. The intraocular pressure change from the baseline ranged from -3.9 mmHg after 4 weeks to -4.48 mmHg after 12 weeks. The most frequently related adverse effect was abnormal taste and blurred vision. Conclusion. Brinzolamide 1% (b.i.d.) used adjunctively with travoprost 0.004% (q.d.) lowers intraocular pressure significantly compared to travoprost alone. Both drugs were well tolerated and safe in the studied patients.

scholarly journals Clinical outcomes of combined Preserflo Microshunt implantation and cataract surgery in open-angle glaucoma patients

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
José M. Martínez-de-la-Casa ◽  
Federico Saenz-Francés ◽  
Laura Morales-Fernandez ◽  
Lucia Perucho ◽  
Carmen Mendez ◽  
...  
Keyword(s):  
Intraocular Pressure ◽  
Adverse Events ◽  
Cataract Surgery ◽  
Open Angle Glaucoma ◽  
Open Angle ◽  
Open Label ◽  
Sample Mean ◽  
Open Label Study ◽  
Label Study ◽  
Wound Leakage

AbstractTo assess the effectiveness and safety of the Preserflo Microshunt (PMS) implantation combined with cataract surgery in open-angle glaucoma (OAG) patients. Retrospective, open-label study conducted on insufficiently controlled OAG patients, who underwent a PMS implant procedure with mitomycin-C 0.2%, either alone or in combination with cataract surgery, and were followed for at least 12 months. Success was defined as an intraocular pressure (IOP) ≤ 18 mmHg and a reduction of at least 20% without (complete) or with (qualified) hypotensive medication. Fifty-eight eyes were included in the study, 35 eyes underwent PMS alone and 23 underwent PMS + Phaco. In the overall study sample, mean IOP was significantly lowered from 21.5 ± 3.3 mmHg at baseline to 14.6 ± 3.5 mmHg at month 12 (p < 0.0001). The IOP was significantly reduced in both groups; p < 0.0001 each, respectively. Ocular hypotensive medication was significantly reduced (p < 0.0001) in both groups. No significant differences were observed in IOP lowering or medication reduction between groups. At month 12, 62.1% eyes were considered as complete success and 82.8% eyes as qualified success. The most common adverse events were device close-to-endothelium, conjunctival fibrosis, and wound leakage. PMS, either alone or in combination with phacoemulsification, may be considered as a valuable option for treating OAG patients.

Sign in / Sign up

Export Citation Format

Share Document